Royal Bank of Canada
CYTK icon

Royal Bank of Canada’s Cytokinetics CYTK Stock Holding History

Royal Bank of Canada’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-97,400
Closed -$925K – 5962
2014
Q1 		$925K Buy
+97,400
New +$881K ﹤0.01% 2829

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada's CYTK Position: Q1 2026 in Review

Royal Bank of Canada reduced its Cytokinetics (CYTK) stake by 42% in Q1 2026, selling an estimated $819K and leaving 17,692 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #3508.

Royal Bank of Canada first reported a position in CYTK in Q3 2013 and has held it in 42 quarters since. The position peaked at $3.75M in Q3 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Royal Bank of Canada held 17,692 shares of Cytokinetics worth $1.17M as of Q1 2026.
  • Royal Bank of Canada sold 12,880 Cytokinetics shares in Q1 2026, an estimated $819K.
  • Cytokinetics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #3508 holding.
  • Royal Bank of Canada first reported a position in Cytokinetics in Q3 2013 and has held it in 42 quarters since.
  • Royal Bank of Canada's Cytokinetics position peaked at $3.75M in Q3 2025.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.